Outcome of exercise of warrants of series TO1 in S2Medical AB (publ)

During the period between the 6th – 20th October 2022, holders of warrants of series TO1 have been able to subscribe for B shares with the support of warrants. A total of 6,903,128 warrants of series TO1 were exercised. In total, approximately SEK 5,660,564.96 million SEK will be added to the Company from TO1.

Through the exercised number of warrants, 6,903,128 new B shares are added to the Company, the total new number of B shares will therefore amount to 29,366,669 and the total number of shares in the Company 32,491,669. The share capital increases by SEK 404,353.80, which means that the total share capital in the Company after the outcome amounts to SEK 1,903,214.00.

The information was submitted for publication, through the agency of the contact person, on 25-10-2022 12:30 CET.

Contact Details
Petter Sivlér – CEO, S2Medical AB (publ)
Telephone: +46 (0)8-70 000 50
E-mail: petter.sivler@s2m.se

Certified Adviser
Vator Securities AB
Telephone +46 (0)8-580 065 99
Website: www.vatorsec.se 
E-mail: ca@vatorsec.se

About S2Medical 

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health care.

Share's ticker: S2M

Share's ISIN-code: SE0011725084